RU2015128914A - Составы лоразепама с контролируемым высвобождением - Google Patents
Составы лоразепама с контролируемым высвобождением Download PDFInfo
- Publication number
- RU2015128914A RU2015128914A RU2015128914A RU2015128914A RU2015128914A RU 2015128914 A RU2015128914 A RU 2015128914A RU 2015128914 A RU2015128914 A RU 2015128914A RU 2015128914 A RU2015128914 A RU 2015128914A RU 2015128914 A RU2015128914 A RU 2015128914A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- lorazepam
- composition according
- day
- controlled release
- Prior art date
Links
- 229960004391 lorazepam Drugs 0.000 title claims 15
- 238000013270 controlled release Methods 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title claims 8
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750792P | 2013-01-09 | 2013-01-09 | |
| US61/750,792 | 2013-01-09 | ||
| US201361762836P | 2013-02-08 | 2013-02-08 | |
| US61/762,836 | 2013-02-08 | ||
| PCT/US2014/010863 WO2014110248A1 (en) | 2013-01-09 | 2014-01-09 | Controlled release formulations of lorazepam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015128914A true RU2015128914A (ru) | 2017-02-14 |
Family
ID=50030512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015128914A RU2015128914A (ru) | 2013-01-09 | 2014-01-09 | Составы лоразепама с контролируемым высвобождением |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP2943186A1 (es) |
| JP (1) | JP2016504391A (es) |
| KR (1) | KR20150127037A (es) |
| CN (1) | CN105188682A (es) |
| AU (1) | AU2014205356A1 (es) |
| BR (1) | BR112015016322A8 (es) |
| CA (1) | CA2897313A1 (es) |
| CL (1) | CL2015001921A1 (es) |
| HK (1) | HK1213803A1 (es) |
| IL (1) | IL239778A0 (es) |
| MX (1) | MX2015008757A (es) |
| PE (1) | PE20151431A1 (es) |
| PH (1) | PH12015501533A1 (es) |
| RU (1) | RU2015128914A (es) |
| SG (1) | SG11201505352RA (es) |
| WO (1) | WO2014110248A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020008756A2 (pt) | 2017-11-01 | 2020-10-13 | Edgemont Pharmaceuticals, LLC Trust | composições farmacêuticas orais de lorazepam resistentes a álcool |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL298071A (es) | 1963-06-04 | |||
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3786813A (en) | 1972-12-27 | 1974-01-22 | Alza Corp | Drug delivery device with self actuated mechanism for retaining device in selected area |
| US4361545A (en) | 1979-05-21 | 1982-11-30 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion |
| AU4064285A (en) * | 1984-03-21 | 1985-10-11 | American Home Products Corporation | Sustained release pharmaceutical capsules |
| US4624847A (en) | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
| US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| CO5140079A1 (es) * | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
| EP1347748A2 (en) | 2000-12-05 | 2003-10-01 | MacGregor, Alexander | Hydrostatic delivery system for controlled delivery of agent |
| WO2003005951A2 (en) | 2001-07-10 | 2003-01-23 | Teva Pharmaceutical Industries Ltd. | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| US6703045B2 (en) | 2001-08-21 | 2004-03-09 | Council Of Scientific & Industrial Research | Composition and method for maintaining blood glucose level |
| BR0302017B1 (pt) * | 2003-06-02 | 2014-10-29 | Ems Sigma Pharma Ltda | Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos |
| KR100822519B1 (ko) * | 2005-02-15 | 2008-04-16 | 주식회사종근당 | 위장 내에서 제어방출되는 단일 매트릭스 정제 |
-
2014
- 2014-01-09 AU AU2014205356A patent/AU2014205356A1/en not_active Abandoned
- 2014-01-09 BR BR112015016322A patent/BR112015016322A8/pt active Search and Examination
- 2014-01-09 CA CA2897313A patent/CA2897313A1/en not_active Abandoned
- 2014-01-09 WO PCT/US2014/010863 patent/WO2014110248A1/en not_active Ceased
- 2014-01-09 KR KR1020157020972A patent/KR20150127037A/ko not_active Withdrawn
- 2014-01-09 HK HK16101886.7A patent/HK1213803A1/zh unknown
- 2014-01-09 EP EP14702134.9A patent/EP2943186A1/en not_active Withdrawn
- 2014-01-09 PE PE2015001249A patent/PE20151431A1/es not_active Application Discontinuation
- 2014-01-09 MX MX2015008757A patent/MX2015008757A/es unknown
- 2014-01-09 JP JP2015551871A patent/JP2016504391A/ja active Pending
- 2014-01-09 CN CN201480012337.2A patent/CN105188682A/zh active Pending
- 2014-01-09 SG SG11201505352RA patent/SG11201505352RA/en unknown
- 2014-01-09 RU RU2015128914A patent/RU2015128914A/ru unknown
-
2015
- 2015-07-05 IL IL239778A patent/IL239778A0/en unknown
- 2015-07-06 CL CL2015001921A patent/CL2015001921A1/es unknown
- 2015-07-07 PH PH12015501533A patent/PH12015501533A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2897313A1 (en) | 2014-07-17 |
| HK1213803A1 (zh) | 2016-07-15 |
| WO2014110248A1 (en) | 2014-07-17 |
| BR112015016322A8 (pt) | 2018-01-23 |
| BR112015016322A2 (pt) | 2017-07-11 |
| IL239778A0 (en) | 2015-08-31 |
| CL2015001921A1 (es) | 2015-12-18 |
| SG11201505352RA (en) | 2015-08-28 |
| PH12015501533A1 (en) | 2015-10-05 |
| KR20150127037A (ko) | 2015-11-16 |
| CN105188682A (zh) | 2015-12-23 |
| AU2014205356A1 (en) | 2015-07-30 |
| PE20151431A1 (es) | 2015-09-23 |
| MX2015008757A (es) | 2016-02-05 |
| EP2943186A1 (en) | 2015-11-18 |
| JP2016504391A (ja) | 2016-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525343A5 (es) | ||
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| JP2018507243A5 (es) | ||
| RU2016143979A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2019529570A5 (es) | ||
| JP2017533211A5 (es) | ||
| RU2003100507A (ru) | Фармацевтические композиции | |
| JP2016505050A5 (es) | ||
| JP2018039810A5 (es) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| Samborski et al. | Intra‐articular treatment of arthritides and activated osteoarthritis with the 5‐HT3 receptor antagonist tropisetron. A double‐blind study compared with methylprednisolone | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| RU2015128914A (ru) | Составы лоразепама с контролируемым высвобождением | |
| BR0008054A (pt) | Forma cristalina de eplerenona | |
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| JP2012041314A5 (es) | ||
| RU2011113733A (ru) | Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах | |
| RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
| RU2015128915A (ru) | Составы лоразепама с замедленным высвобождением | |
| WO2011108882A3 (ko) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 | |
| TW200920371A (en) | A combination treatment | |
| JP2016504390A5 (es) | ||
| JP3935539B2 (ja) | フマル酸ケトチフェン含有医薬組成物 | |
| KR102857391B1 (ko) | 고함량의 천연물 유래 유효성분을 포함하는 약학 조성물 |